Log in

NASDAQ:XBIT - XBiotech Stock Price, Forecast & News

$14.92
-0.14 (-0.93 %)
(As of 02/19/2020 06:32 AM ET)
Today's Range
$14.61
Now: $14.92
$15.25
50-Day Range
$14.92
MA: $20.79
$24.90
52-Week Range
$6.76
Now: $14.92
$26.40
Volume797,000 shs
Average Volume1.18 million shs
Market Capitalization$613.02 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIT
CUSIPN/A
Phone512-386-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.16 per share

Profitability

Net Income$-21,140,000.00

Miscellaneous

Employees56
Market Cap$613.02 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.


XBiotech (NASDAQ:XBIT) Frequently Asked Questions

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

How were XBiotech's earnings last quarter?

XBiotech Inc (NASDAQ:XBIT) announced its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). View XBiotech's Earnings History.

When is XBiotech's next earnings date?

XBiotech is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for XBiotech.

What price target have analysts set for XBIT?

1 brokers have issued 1 year price objectives for XBiotech's shares. Their forecasts range from $28.00 to $28.00. On average, they anticipate XBiotech's stock price to reach $28.00 in the next year. This suggests a possible upside of 87.7% from the stock's current price. View Analyst Price Targets for XBiotech.

What is the consensus analysts' recommendation for XBiotech?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XBiotech.

Has XBiotech been receiving favorable news coverage?

Media coverage about XBIT stock has trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. XBiotech earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for XBiotech.

Are investors shorting XBiotech?

XBiotech saw a increase in short interest in January. As of January 15th, there was short interest totalling 3,590,000 shares, an increase of 10.8% from the December 31st total of 3,240,000 shares. Based on an average daily volume of 424,000 shares, the short-interest ratio is currently 8.5 days. Approximately 20.3% of the company's stock are sold short. View XBiotech's Current Options Chain.

Who are some of XBiotech's key competitors?

What other stocks do shareholders of XBiotech own?

Who are XBiotech's key executives?

XBiotech's management team includes the folowing people:
  • Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)
  • Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)
  • Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)
  • Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)
  • Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board

When did XBiotech IPO?

(XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

Who are XBiotech's major shareholders?

XBiotech's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (0.82%), Sofinnova Investments Inc. (0.59%), Bank of New York Mellon Corp (0.16%), Russell Investments Group Ltd. (0.14%), Charles Schwab Investment Management Inc. (0.12%) and EAM Investors LLC (0.10%). Company insiders that own XBiotech stock include Fondation Rennes, Queena Han, W Thorpe Mckenzie and W Thorpe Mckenzie. View Institutional Ownership Trends for XBiotech.

Which major investors are selling XBiotech stock?

XBIT stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., EAM Investors LLC, State Street Corp, Strs Ohio, New York State Common Retirement Fund and Bank of America Corp DE. View Insider Buying and Selling for XBiotech.

Which major investors are buying XBiotech stock?

XBIT stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., California Public Employees Retirement System, Silverleafe Capital Partners LLC, Virtus ETF Advisers LLC, UBS Group AG, Trexquant Investment LP, Caxton Associates LP and Zebra Capital Management LLC. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes and W Thorpe Mckenzie. View Insider Buying and Selling for XBiotech.

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $14.92.

How big of a company is XBiotech?

XBiotech has a market capitalization of $613.02 million. The biopharmaceutical company earns $-21,140,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. XBiotech employs 56 workers across the globe.View Additional Information About XBiotech.

What is XBiotech's official website?

The official website for XBiotech is http://www.xbiotech.com/.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]


MarketBeat Community Rating for XBiotech (NASDAQ XBIT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  462
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel